Commentary· 2006
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging
Back to all molecules
Human researchHistorical FDA product · discontinued
Sermorelin
GHRH (1–29) analog
Also indexed as: GRF 1-29 · Geref
What this evidence does not tell us
The linked article is a commentary, not a randomized anti-aging trial. Historical Geref approval and discontinuation do not make current compounded formulations FDA-approved.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
10 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
10 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
Sermorelin is an analog of the first 29 amino acids of growth hormone-releasing hormone. Historical Geref products were approved and later discontinued; current compounded products require separate regulatory interpretation.
Mechanism of action
GHRH / GH–IGF-1
Acts at pituitary GHRH receptors to stimulate endogenous growth hormone release, with downstream IGF-1 signaling. A functioning hypothalamic-pituitary system and clinical context influence responses.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Human evidence is still developing
- Limited evidence
- Early research
- Human researchCurrent category
- Human outcomes
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: The linked article is a commentary, not a randomized anti-aging trial. Historical Geref approval and discontinuation do not make current compounded formulations FDA-approved.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Historical pediatric and diagnostic research exists; the cited adult-aging article is a commentary rather than a clinical trial.
Regulatory evidence
Geref was historically FDA-approved and later discontinued; FDA determined withdrawal from sale was not for safety or effectiveness reasons. Current compounded preparations are not FDA-approved finished drugs.
Potential research applications
Pituitary GH response and historical pediatric GH-deficiency research.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Potential endocrine effects, glucose changes, fluid retention and hypersensitivity require clinical assessment. Long-term anti-aging use lacks adequate evidence.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Regulatory status · United States
Historical FDA product · discontinued
Geref was historically FDA-approved and later discontinued; FDA determined withdrawal from sale was not for safety or effectiveness reasons. Current compounded preparations are not FDA-approved finished drugs.
Read the official regulatory sourceRegulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.